Repligen Corp. (RGEN) Position Raised by Ameriprise Financial Inc.
Ameriprise Financial Inc. raised its position in shares of Repligen Corp. (NASDAQ:RGEN) by 13.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 602,779 shares of the company’s stock after buying an additional 73,122 shares during the period. Ameriprise Financial Inc. owned about 1.78% of Repligen Corp. worth $16,492,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of RGEN. Acrospire Investment Management LLC purchased a new stake in shares of Repligen Corp. during the first quarter worth $106,000. Envestnet Asset Management Inc. raised its stake in shares of Repligen Corp. by 75.5% in the first quarter. Envestnet Asset Management Inc. now owns 5,527 shares of the company’s stock worth $148,000 after buying an additional 2,377 shares during the period. Legal & General Group Plc raised its stake in shares of Repligen Corp. by 10.2% in the first quarter. Legal & General Group Plc now owns 6,737 shares of the company’s stock worth $184,000 after buying an additional 623 shares during the period. BB&T Corp purchased a new stake in shares of Repligen Corp. during the second quarter worth $241,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Repligen Corp. by 122.3% in the second quarter. BNP Paribas Arbitrage SA now owns 10,542 shares of the company’s stock worth $288,000 after buying an additional 5,800 shares during the period. Institutional investors own 89.38% of the company’s stock.
Repligen Corp. (NASDAQ:RGEN) traded down 2.858% on Thursday, hitting $32.465. The stock had a trading volume of 197,090 shares. Repligen Corp. has a 52-week low of $20.07 and a 52-week high of $37.25. The firm’s 50-day moving average is $31.58 and its 200-day moving average is $27.43. The company has a market cap of $1.10 billion, a P/E ratio of 129.860 and a beta of 1.29.
Repligen Corp. (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.03. The company earned $29.20 million during the quarter, compared to analyst estimates of $24.75 million. Repligen Corp. had a return on equity of 10.74% and a net margin of 8.69%. The firm’s revenue for the quarter was up 35.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.11 earnings per share. Equities research analysts anticipate that Repligen Corp. will post $0.44 earnings per share for the current fiscal year.
Several research firms have recently commented on RGEN. Zacks Investment Research raised Repligen Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, July 21st. Jefferies Group reissued a “hold” rating and issued a $28.00 price target on shares of Repligen Corp. in a research report on Monday, June 13th.
In other news, Director Thomas F. Ryan, Jr. sold 5,000 shares of the firm’s stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $26.60, for a total transaction of $133,000.00. Following the completion of the transaction, the director now directly owns 12,094 shares in the company, valued at $321,700.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Thomas F. Ryan, Jr. sold 2,700 shares of the firm’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $32.58, for a total value of $87,966.00. Following the transaction, the director now owns 9,394 shares of the company’s stock, valued at $306,056.52. The disclosure for this sale can be found here. 2.30% of the stock is owned by corporate insiders.
About Repligen Corp.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
Receive News & Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related companies with MarketBeat.com's FREE daily email newsletter.